Pancreatic Enzyme Replacement Therapy: Shortages
The question
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 4 March 2025 to Question 35462 on Pancreatic Enzyme Replacement Therapy shortages, what the (a) dates and (b) attendees were of meetings held with (i) clinicians, (ii) patient advocacy groups, (iii) affected charities, and (iv) manufacturers of pancreatic enzyme replacement therapy to discuss (A) shortages and (B) steps to increase supply.
Answered by Karin Smyth
The Department is in regular discussions with the suppliers of pancreatic enzyme replacement therapy on the latest stock availability and the actions being taken to mitigate the supply issue that is affecting the whole of the United Kingdom. We have had discussions with representatives from UK and global supply teams, and will continue these meetings to understand what more can be done to add further resilience to the UK market.
The Department has worked with specialist clinicians from impacted therapeutic areas, the Medicine Shortage Response Group, and the Specialist Pharmacy Service to devise guidance for healthcare professionals with comprehensive management advice for the treatment of patients during this time.
The Department meets regularly with the affected patient advocacy groups and charities, including Pancreatic Cancer UK, Cystic Fibrosis Trust, Guts UK, and Neuroendocrine Cancer UK to ensure they are kept informed on the latest supply picture and any communications issued to healthcare professionals.
Verbatim has judged this answer against the question that was actually asked — answered, partly answered, or evaded. Sign in to see the verdict →